From: Patricia Pochelon <[email protected]> Date: January 25, 2016 at 8:28:21 PM GMT+5 To: "Prof. Muzzaffar Lateef Gill" Subject: Amendment - ILC 2016 - Abstract notification ABSTRACT NOTIFICATION - EASL - THE INTERNATIONAL LIVER CONGRESS™ 2016 Professor Muzzaffar Gill MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD Islamabad, Pakistan Our Reference: THU-364 Dear Professor Gill Scientific Programme Committee, we are […]

From: Patricia Pochelon <[email protected]> Date: January 25, 2016 at 8:28:21 PM GMT+5 To: "Prof. Muzzaffar Lateef Gill" Subject: Amendment - ILC 2016 - Abstract notification ABSTRACT NOTIFICATION - EASL - THE INTERNATIONAL LIVER CONGRESS™ 2016 Professor Muzzaffar Gill MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD Islamabad, Pakistan Our Reference: THU-364 Dear Professor Gill Scientific Programme Committee, we are […]

SIDRA GILL, NOSHEEN YOUSUF, AMMARA NAWAZ, RABBEA NAZIR, MUZZAFFAR GILL Background: ERCP is commonly performed in cirrhotics, they are at increased risk of bleeding after ERCP, but the incidence and risk-factors in this population is not well described. The aim of this study was to examine the incidence of post-ERCP complications. Methods: We evaluated all […]

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN Background and Aims: Sofosbuvir + Ribavirin is gold standard for chronic HEP-C patients. We evaluated the safety and efficacy of sofosbuvir and ribavirin in chronic HEP-C G3 patients. Methods: We prospectively enrolled 150 patients with chronic HEP- […]

SIDRA GILL NOSHEEN YOUSUF, AMMARA NAWAZ , RABBEA NAZIR, MUZZAFFAR GILL Background: Recurrent hepatitis occurs in the vast majority of HCV-positive recipients who are viremic at the time of Liver Transplantation (LT). We evaluated safety and efficacy of all oral antiviral therapy (Tx) with Sofosbuvir plus Ribavirin in a population of HCV G3-infected patients. Methods: […]

SIDRA GILL, NOSHEEN YOUSAF, FAIZA IRFAN, AMMARA NAWAZ, UZMA FEYAZ QAZI, MUZZAFFAR GILL MAROOF INTERNATIONAL HOSPITAL, ISLAMABAD, PAKISTAN Background: Sovaldi, Ribavirin and PEG-Interferon is gold standard therapy for chronic HEP-C patients. It is recommended both for treatment naive and experienced patients. We evaluated the safety and efficacy of this combination in naïve chronic HEP-C G3 […]